Not really. The definitive trial might include these domains but the question being answered becomes quite different.
Different trials for each. There is a fairly worked up proposal for a "definitive treatment trial" but that can't easily get at Q's on empiric IVIG & anti-toxins. The latter much harder as syndromes caused by a range of bacteria some where interventions might help and some where we presume does zero
There are a few different irons in the fire. One focused on definitive treatment of GAS. One focused on empirical treatment of syndromes. IVIG at least in the UK would be very difficult to deliver via an ACORN style approach for this indication.
Agree - hence our conclusion in editorial that these data can't tell us that much. We've been thinking about how to actually solve this problem - see www.clinicalmicrobiologyandinfection.com/article/S119... Possibly using an ACORN type approach to facilitate the trial design
In Lancet ID www.thelancet.com/journals/lan...@drtoddlee.bsky.social
Streptococcus pyogenes, or group A streptococcus, remains a major global pathogen, responsible for a wide spectrum of diseases ranging from pharyngitis to severe invasive group A streptococcus (iGAS) ...
Academic Clinical Fellowship in Infectious Diseases @lshtm.bsky.socialoriel.nhs.uk/Web/PermaLin... by 31st October. Get in touch if you want to discuss the opportunities.